Status:
RECRUITING
An European Multi-centre Cohort Study for Unravelling Pharmacokinetic and Genetic Factors Underlying Post-ERCP Pancreatitis
Lead Sponsor:
Radboud University Medical Center
Conditions:
Post-ERCP Acute Pancreatitis
Eligibility:
All Genders
18+ years
Brief Summary
Endoscopic retrograde cholangiopancreatography (ERCP) comes with a risk for post-ERCP pancreatitis (PEP), which accounts for considerable morbidity, high healthcare expenditure, and death. The pathoph...
Detailed Description
This study is a hypothesis driven and hypothesis free analyses of PEP risk variants. Integrative analysis of NSAID pharmacokinetics and-genetics in PEP patients.
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- written informed consent
- Indication to undergo an ERCP
Exclusion
- Pancreatic cancer
- Chronic pancreatitis
- Ongoing acute pancreatitis
- Altered anatomy, defined as anatomical variations in which gall and/or pancreatic juices (in case of pancreatic duct interventions) do not enter the duodenum by way of the ampulla of Vater.
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT05267379
Start Date
March 1 2022
End Date
December 1 2027
Last Update
April 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
RadboudUMC
Nijmegen, Gelderland, Netherlands, 6525 GA